Clinical Research Directory
Browse clinical research sites, groups, and studies.
PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.
Sponsor: Jules Bordet Institute
Summary
This is a descriptive, prospective, single centre study. This study will assess PSMA expression via the uptake of radiolabelled PSMA-ligand using PET/CT imaging in mTNBC lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory mTNBC using the Lutetium-177 radiolabelled PSMA.
Official title: PRISMA: A Single-centre, Prospective Phase II Imaging Study Using PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2022-05-30
Completion Date
2025-12
Last Updated
2025-07-18
Healthy Volunteers
No
Conditions
Interventions
Ga-PSMA PET/CT
Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment
Locations (1)
Institut Jules Bordet
Brussels, Belgium